Compare · RMD vs SGHT
RMD vs SGHT
Side-by-side comparison of ResMed Inc. (RMD) and Sight Sciences Inc. (SGHT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and SGHT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $33.69B, about 56.0x SGHT ($601.9M).
- RMD has been more active in the news (12 items in the past 4 weeks vs 5 for SGHT).
- RMD has more recent analyst coverage (25 ratings vs 21 for SGHT).
- Company
- ResMed Inc.
- Sight Sciences Inc.
- Price
- -
- -
- Market cap
- $33.69B
- $601.9M
- 1M return
- -1.16%
- -
- 1Y return
- -2.13%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 12
- 5
- Recent ratings
- 25
- 21
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Sight Sciences Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Latest RMD
- Chairman and CEO Farrell Michael J. covered exercise/tax liability with 8,111 units of ResMed Common Stock, decreasing direct ownership by 2% to 471,774 units (SEC Form 4) (tax withholding)
- Chief Financial Officer Bloomer Aaron covered exercise/tax liability with 1,095 units of ResMed Common Stock, decreasing direct ownership by 12% to 7,977 units (SEC Form 4) to satisfy withholding tax
- Director Farrell Peter C covered exercise/tax liability with 169 units of ResMed Common Stock, decreasing direct ownership by 0.33% to 51,634 units (SEC Form 4) (withholding obligation)
- Director De Witte Jan covered exercise/tax liability with 60 units of ResMed Common Stock, decreasing direct ownership by 1% to 4,201 units (SEC Form 4) (for tax liability)
- Director Gill Harjit covered exercise/tax liability with 36 units of ResMed Common Stock, decreasing direct ownership by 0.33% to 10,904 units (SEC Form 4) (withholding tax)
- Global General Counsel Rider Michael J covered exercise/tax liability with 1,944 units of ResMed Common Stock, decreasing direct ownership by 16% to 10,417 units (SEC Form 4) (withholding obligation)
- Chairman and CEO Farrell Michael J. exercised 4,993 units of ResMed Common Stock at a strike of $146.34 and sold $1,175,089 worth of ResMed Common Stock (4,993 units at $235.35) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed downgraded by Canaccord Genuity
- SEC Form 10-Q filed by ResMed Inc.
- SEC Form 8-K filed by ResMed Inc.
Latest SGHT
- Sight Sciences to Present at Two Upcoming Investor Conferences
- Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids
- SEC Form 10-Q filed by Sight Sciences Inc.
- Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance
- Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
- H.C. Wainwright initiated coverage on Sight Sciences with a new price target
- EVP, Operations & R&D Taylor Brenton sold $26,453 worth of shares (2,988 units at $8.85) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Bauerlein Alison sold $223,627 worth of shares (25,260 units at $8.85) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Rodberg James sold $63,812 worth of shares (7,208 units at $8.85) as part of a pre-agreed trading plan (SEC Form 4)